secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268948
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports $14.6M cash; Auxora shows 53% hospital stay reduction in CRSPA cohort
--------------------------------------------------------------------------------

- Preliminary cash, equivalents, and short-term investments of $14.6M as of Sept 30, 2023; expected to fund operations through Q3 2024.
- Auxora (zegocractin) reduced average hospital stay from 13.4 to 6.3 days (53% reduction) in initial cohort of CRSPA study vs historical control.
- No patients treated with Auxora required total parenteral nutrition (TPN) vs 68.8% in control.
- Recommended dose established for children with ALL experiencing asparaginase-associated pancreatitis: dose level 1.
- Data to be presented at ASH Meeting Dec 9-12, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523268948/0001193125-23-268948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523268948/d565256d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer